IL187503D0 - Stable and soluble antibodies - Google Patents

Stable and soluble antibodies

Info

Publication number
IL187503D0
IL187503D0 IL187503A IL18750307A IL187503D0 IL 187503 D0 IL187503 D0 IL 187503D0 IL 187503 A IL187503 A IL 187503A IL 18750307 A IL18750307 A IL 18750307A IL 187503 D0 IL187503 D0 IL 187503D0
Authority
IL
Israel
Prior art keywords
stable
soluble antibodies
antibodies
soluble
Prior art date
Application number
IL187503A
Original Assignee
Esbatech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US68797105P priority Critical
Priority to US78535306P priority
Priority to PCT/CH2006/000300 priority patent/WO2006131013A2/en
Application filed by Esbatech Ag filed Critical Esbatech Ag
Publication of IL187503D0 publication Critical patent/IL187503D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/522CH1 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
IL187503A 2005-06-07 2007-11-20 Stable and soluble antibodies IL187503D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US68797105P true 2005-06-07 2005-06-07
US78535306P true 2006-03-23 2006-03-23
PCT/CH2006/000300 WO2006131013A2 (en) 2005-06-07 2006-06-06 STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα

Publications (1)

Publication Number Publication Date
IL187503D0 true IL187503D0 (en) 2008-03-20

Family

ID=37193351

Family Applications (2)

Application Number Title Priority Date Filing Date
IL187503A IL187503D0 (en) 2005-06-07 2007-11-20 Stable and soluble antibodies
IL243270A IL243270D0 (en) 2005-06-07 2015-12-21 Stable and soluble antibodies inhibiting tnfα

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL243270A IL243270D0 (en) 2005-06-07 2015-12-21 Stable and soluble antibodies inhibiting tnfα

Country Status (21)

Country Link
US (5) US8067547B2 (en)
EP (3) EP1891110A2 (en)
JP (2) JP5089582B2 (en)
KR (2) KR101539545B1 (en)
CN (2) CN102924597A (en)
AU (1) AU2006255415B2 (en)
BR (1) BRPI0611765A2 (en)
CA (1) CA2609999C (en)
DK (1) DK2390267T3 (en)
ES (1) ES2424042T3 (en)
HK (2) HK1164891A1 (en)
HR (1) HRP20130632T1 (en)
IL (2) IL187503D0 (en)
MX (1) MX2007015280A (en)
NZ (1) NZ563580A (en)
PH (1) PH12012500758A1 (en)
PL (1) PL2390267T3 (en)
PT (1) PT2390267E (en)
RS (1) RS52861B (en)
RU (1) RU2415151C2 (en)
WO (1) WO2006131013A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
RU2415151C2 (en) 2005-06-07 2011-03-27 Эсбатек Аг STABLE AND SOLUBLE ANTIBODIES, INHIBITING TNFα
LT2046382T (en) * 2006-07-10 2016-12-12 Esbatech, An Alcon Biomedical Research Unit Llc scFv ANTIBODIES WHICH PASS EPITHELIAL AND/OR ENDOTHELIAL LAYERS
AU2016200367B2 (en) * 2006-07-10 2017-10-12 Esbatech, An Alcon Biomedical Research Unit Llc scFv antibodies which pass epithelial and/or endothelial layers
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
WO2008121615A2 (en) * 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
CN101688200B (en) 2007-06-25 2012-08-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 Sequence based engineering and optimization of single chain antibodies
CA2689941C (en) * 2007-06-25 2019-10-29 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
AU2008303582A1 (en) * 2007-09-25 2009-04-02 Intervet International B.V. Vaccine for the treatment of osteoarthritis
ES2556214T3 (en) * 2007-11-12 2016-01-14 U3 Pharma Gmbh AXL antibodies
EP2243031B1 (en) * 2008-01-21 2012-05-30 Janssen Biotech, Inc. Methods of predicting antibody solubility
EP2240515A1 (en) * 2008-02-05 2010-10-20 Delenex Therapeutics AG Antigen-binding polypeptides against cartilage degeneration
CN102076716A (en) * 2008-06-25 2011-05-25 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 Stable and soluble antibodies inhibiting tnfa
HUE034827T2 (en) 2008-06-25 2018-03-28 Esbatech Alcon Biomed Res Unit Solubility optimization of immunobinders
PT2307458T (en) * 2008-06-25 2018-07-18 Esbatech Alcon Biomed Res Unit Humanization of rabbit antibodies using a universal antibody framework
CN104004094B (en) 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 The humanization of the rabbit antibody carried out using universal antibody framework
CN102089431A (en) 2008-06-30 2011-06-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 Functionalized polypeptides
CA2730178A1 (en) * 2008-07-10 2010-01-14 Esbatech, An Alcon Biomedical Research Unit Llc Methods and compositions for enhanced delivery of macromolecules
EP2270053A1 (en) * 2009-05-11 2011-01-05 U3 Pharma GmbH Humanized AXL antibodies
MX2011011825A (en) * 2009-05-11 2011-12-06 U3 Pharma Gmbh Humanized axl antibodies.
SG184473A1 (en) 2010-04-07 2012-11-29 Abbvie Inc Tnf-alpha binding proteins
KR20130116888A (en) * 2010-11-12 2013-10-24 넥타르 테라퓨틱스 Conjugates of an il-2 moiety and a polymer
AR084210A1 (en) * 2010-12-08 2013-05-02 Abbott Lab Binding proteins TNF-a
JP6431372B2 (en) 2011-10-25 2018-11-28 プロシーナ バイオサイエンシーズ リミテッド Antibody formulations and methods
CN104870015B (en) 2012-11-05 2019-07-30 德勒尼克斯治疗股份公司 The binding members of IL-1 β
SG11201504897YA (en) * 2012-12-21 2015-07-30 Glenmark Pharmaceuticals Sa Anti her2 antibody formulation
CN106170298A (en) 2013-10-16 2016-11-30 安口生物公司 For improving the buffer formulation of Antibody stability
JP6618912B2 (en) 2013-12-20 2019-12-11 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Improved recombinant polypeptide production method
RU2706551C2 (en) * 2014-03-26 2019-11-19 Селл Медика Свитзерлэнд Аг Binding members to tnf-alpha
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
HUE029849T2 (en) 2014-05-23 2017-04-28 Ares Trading Sa Liquid pharmaceutical composition
ES2607489T3 (en) 2014-05-23 2017-03-31 Ares Trading S.A. liquid pharmaceutical composition
EP3165928B1 (en) * 2015-11-06 2019-01-09 Promise Advanced Proteomics A method for quantifying anti-tnf antibodies
EA201892090A1 (en) 2016-03-17 2019-02-28 Нумаб Инновейшн Аг ANTIBODIES TO TNF-α AND THEIR FUNCTIONAL FRAGMENTS
US20190092850A1 (en) 2016-03-17 2019-03-28 Numab Innovation Ag Anti-TNFalpha-Antibodies and Functional Fragments Thereof
EP3219726A1 (en) 2016-03-17 2017-09-20 Tillotts Pharma AG Anti-tnf alpha-antibodies and functional fragments thereof
EP3219727A1 (en) 2016-03-17 2017-09-20 Tillotts Pharma AG Anti-tnf alpha-antibodies and functional fragments thereof
EP3430041A1 (en) 2016-03-17 2019-01-23 Numab Innovation AG Anti-tnfalpha-antibodies and functional fragments thereof
EP3409688A1 (en) 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
EP3456739A1 (en) 2017-09-19 2019-03-20 Tillotts Pharma Ag Use of anti-tnfalpha antibodies for treating wounds
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
EP3459527A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
EP3459528A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2000318A (en) 1933-05-22 1935-05-07 James H Cannon Cord connecter
US2200203A (en) 1938-12-16 1940-05-07 William W Heintz Legend sheet and method of application
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5644034A (en) 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
US5198030A (en) 1991-06-18 1993-03-30 E. I. Du Pont De Nemours And Company Bead edge guide for use in slide-bead coating
DK0614984T4 (en) 1993-03-05 2010-12-20 Bayer Healthcare Llc Human monoclonal anti-TNF alpha antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE69721548T2 (en) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMAN ANTIBODIES THAT BIND TO HUMAN TNFalpha
AU740284B2 (en) * 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US20030185826A1 (en) 1999-02-24 2003-10-02 Tobinick Edward L. Cytokine antagonists for the treatment of localized disorders
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US7258986B2 (en) 1999-12-28 2007-08-21 Esbatech Ag Intrabodies with defined framework that is stable in a reducing environment and applications thereof
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US6406863B1 (en) * 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
SG97908A1 (en) 2000-08-03 2003-08-20 Inst Data Storage A method and apparatus for load/unload testing of disk drives
US6881407B2 (en) 2000-08-11 2005-04-19 Ashok Amin Method for treating hepatitis
AU2002359495A1 (en) 2001-11-30 2003-06-17 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses
ES2537104T3 (en) * 2002-05-22 2015-06-02 Esbatech, An Alcon Biomedical Research Unit Llc Immunoglobulin framework regions demonstrating enhanced stability in the intracellular environment and their identification methods
RU2415151C2 (en) * 2005-06-07 2011-03-27 Эсбатек Аг STABLE AND SOLUBLE ANTIBODIES, INHIBITING TNFα
CN101688200B (en) * 2007-06-25 2012-08-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 Sequence based engineering and optimization of single chain antibodies

Also Published As

Publication number Publication date
KR101539545B1 (en) 2015-07-24
EP3260465A1 (en) 2017-12-27
PH12012500758B1 (en) 2016-01-11
IL243270D0 (en) 2016-02-29
RS52861B (en) 2013-12-31
US9683034B2 (en) 2017-06-20
KR101457223B1 (en) 2014-11-04
CA2609999C (en) 2017-05-30
JP2008545433A (en) 2008-12-18
CA2609999A1 (en) 2006-12-14
ES2424042T3 (en) 2013-09-26
JP2013027390A (en) 2013-02-07
CN102924597A (en) 2013-02-13
RU2415151C2 (en) 2011-03-27
WO2006131013A2 (en) 2006-12-14
HK1164891A1 (en) 2014-01-24
PL2390267T3 (en) 2013-09-30
US9315572B2 (en) 2016-04-19
AU2006255415B2 (en) 2011-10-06
NZ563580A (en) 2010-09-30
EP2390267A1 (en) 2011-11-30
US8067547B2 (en) 2011-11-29
KR20140071450A (en) 2014-06-11
HRP20130632T1 (en) 2013-11-22
US8691228B2 (en) 2014-04-08
AU2006255415A1 (en) 2006-12-14
US20090263382A1 (en) 2009-10-22
EP2390267B1 (en) 2013-06-05
PH12012500758A1 (en) 2016-01-11
JP5645890B2 (en) 2014-12-24
KR20080031003A (en) 2008-04-07
US20140171634A1 (en) 2014-06-19
PT2390267E (en) 2013-07-16
HK1218653A1 (en) 2017-03-03
RU2007149255A (en) 2009-07-20
US8389693B2 (en) 2013-03-05
BRPI0611765A2 (en) 2011-12-20
WO2006131013A3 (en) 2007-01-25
US20160185850A1 (en) 2016-06-30
US20120064077A1 (en) 2012-03-15
EP1891110A2 (en) 2008-02-27
CN105153306A (en) 2015-12-16
US20130171143A1 (en) 2013-07-04
MX2007015280A (en) 2008-04-08
JP5089582B2 (en) 2012-12-05
DK2390267T3 (en) 2013-08-26

Similar Documents

Publication Publication Date Title
GB2418362B (en) Stent
DK1838733T3 (en) Antibodies directed against Angiopoietin-2 and uses thereof
TWI350762B (en) Particulates
TWI455946B (en) Anti-glypican 3 antibody
HK1116201A1 (en) Novel anti-igf-ir antibodies and uses thereof igf-ir
IL188421D0 (en) Anti-il-23 antibodies, compositions, methods and uses
IL244803D0 (en) Humanized anti-beta7 antibodies and uses therefore
IL187784D0 (en) Antibodies directed to cd20 and uses thereof
EP1767240A4 (en) Stent
PT2099826E (en) Anti-beta-amyloid antibody and uses thereof
AT526987T (en) Dr5 antibodies and their use
IL248917D0 (en) Human anti-il-23 antibodies,compositions, methods and uses
GB0502258D0 (en) Compounds and their use
DE602006013893D1 (en) Polyglutamate-amino acid conjugates and methods
EP1920216A4 (en) Location signposting and orientation
PL2366399T3 (en) Non-cytotoxic protein conjugates
ZA200710264B (en) Anti-IL-6 antibodies, compositions, methods and uses
SI1791565T1 (en) Cysteine engineered antibodies and conjugates
IL179140D0 (en) Antibody drug conjuates and methods
PL1877073T3 (en) Non-cytotoxic protein conjugates
EP1802588A4 (en) Substituted amino-pyrimidones and uses thereof
IL188088D0 (en) Cd19 antibodies and their uses
IL181025D0 (en) Novel anti-igf-ir antibodies and uses thereof
IL221366D0 (en) SOLUBLE zB7RI POLYPEPTIDE AND METHOD USING IT
PL2390267T3 (en) Stable and soluble antibodies inhibiting TNF(alpha)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed